Evoke Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 09, 2023 at 09:00 am EST
Share
Evoke Pharma, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 1.69 million compared to USD 2.01 million a year ago. Basic loss per share from continuing operations was USD 0.51 compared to USD 0.6 a year ago. Diluted loss per share from continuing operations was USD 0.51 compared to USD 0.6 a year ago. Revenue was USD 1.562 million compared to USD 0.832 million a year ago.
For the nine months, net loss was USD 5.8 million compared to USD 6.42 million a year ago. Basic loss per share from continuing operations was USD 1.74 compared to USD 2.09 a year ago. Diluted loss per share from continuing operations was USD 1.74 compared to USD 2.09 a year ago. Revenue was USD 3.504 million compared to USD 1.712 million a year ago.
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.